Article
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)
2024-04-04
Abstract excerpt
<h4>Background</h4> Influenza A results in significant morbidity and mortality. VIR-2482, an engineered human monoclonal antibody with extended half-life, targets a highly conserved epitope on the stem region of influenza A hemagglutinin, and may protect against seasonal and pandemic influenza. <h4>Methods</h4> This double-blind, randomized, placebo-controlled, phase 2 study examined the safety and efficacy of VIR...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4ebcc7e6-b3d8-56e4-bbe0-8f6340fc0d87
- DOI
- 10.1101/2024.04.03.24305209
